Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin

A retrospective multicentric study

P. Schöffski, M. Taron, J. Jimeno, F. Grosso, R. Sanfilipio, P. G. Casali, A. Le Cesne, R. L. Jones, J. Y. Blay, A. Poveda, R. G. Maki, A. Nieto, J. C. Tercero, R. Rosell

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Aim: Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair leads to resistance. On this basis, a retrospective study of mRNA expression of BRCA1 (breast cancer susceptibility 1 gene), XPG (Xeroderma pigmentosum group G gene) and ERCC1 (excision-repair cross complementing group 1 gene) in tumour samples from sarcoma patients treated with trabectedin was conducted, to correlate DNA repair profiles with patient outcome. Materials and methods: Quantification of expression in paraffin embedded tumour samples from 245 patients with advanced sarcomas was performed by qRT-PCR (quantitative real-time polymerase chain reaction). Median values were used as cut-off to define low/high mRNA expression. Results: Low BRCA1 mRNA expression in tumour samples correlated with statistically significant better response to trabectedin. In contrast to other DNA interacting agents, high expression of XPG was significantly correlated with increased response to the drug and high ERCC1 or XPD (Xeroderma pigmentosum group D gene) expression did not have a detrimental impact. A composite signature including low BRCA1 and high ERCC1 and/or XPG identifies a highly sensitive population of sarcomas with significantly improved treatment outcome. Discussion: This retrospective study indicates that the DNA repair profile predicts improved outcomes in advanced sarcoma patients when treated with trabectedin. This clinical utility of this signature should be evaluated in prospective enriching studies in sarcoma and other malignancies for patients sensitive to trabectedin.

Original languageEnglish
Pages (from-to)1006-1012
Number of pages7
JournalEuropean Journal of Cancer
Volume47
Issue number7
DOIs
Publication statusPublished - May 2011

Fingerprint

trabectedin
DNA Repair
Sarcoma
Retrospective Studies
Xeroderma Pigmentosum
Genes
Messenger RNA
Neoplasms
Recombinational DNA Repair
Vulnerable Populations
Paraffin
Real-Time Polymerase Chain Reaction

Keywords

  • DNA repair
  • ET-743
  • Sarcoma
  • Trabectedin
  • Yondelis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin : A retrospective multicentric study. / Schöffski, P.; Taron, M.; Jimeno, J.; Grosso, F.; Sanfilipio, R.; Casali, P. G.; Le Cesne, A.; Jones, R. L.; Blay, J. Y.; Poveda, A.; Maki, R. G.; Nieto, A.; Tercero, J. C.; Rosell, R.

In: European Journal of Cancer, Vol. 47, No. 7, 05.2011, p. 1006-1012.

Research output: Contribution to journalArticle

Schöffski, P, Taron, M, Jimeno, J, Grosso, F, Sanfilipio, R, Casali, PG, Le Cesne, A, Jones, RL, Blay, JY, Poveda, A, Maki, RG, Nieto, A, Tercero, JC & Rosell, R 2011, 'Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study', European Journal of Cancer, vol. 47, no. 7, pp. 1006-1012. https://doi.org/10.1016/j.ejca.2011.01.016
Schöffski, P. ; Taron, M. ; Jimeno, J. ; Grosso, F. ; Sanfilipio, R. ; Casali, P. G. ; Le Cesne, A. ; Jones, R. L. ; Blay, J. Y. ; Poveda, A. ; Maki, R. G. ; Nieto, A. ; Tercero, J. C. ; Rosell, R. / Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin : A retrospective multicentric study. In: European Journal of Cancer. 2011 ; Vol. 47, No. 7. pp. 1006-1012.
@article{c32570374f02406886165412a2f3a99a,
title = "Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study",
abstract = "Aim: Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair leads to resistance. On this basis, a retrospective study of mRNA expression of BRCA1 (breast cancer susceptibility 1 gene), XPG (Xeroderma pigmentosum group G gene) and ERCC1 (excision-repair cross complementing group 1 gene) in tumour samples from sarcoma patients treated with trabectedin was conducted, to correlate DNA repair profiles with patient outcome. Materials and methods: Quantification of expression in paraffin embedded tumour samples from 245 patients with advanced sarcomas was performed by qRT-PCR (quantitative real-time polymerase chain reaction). Median values were used as cut-off to define low/high mRNA expression. Results: Low BRCA1 mRNA expression in tumour samples correlated with statistically significant better response to trabectedin. In contrast to other DNA interacting agents, high expression of XPG was significantly correlated with increased response to the drug and high ERCC1 or XPD (Xeroderma pigmentosum group D gene) expression did not have a detrimental impact. A composite signature including low BRCA1 and high ERCC1 and/or XPG identifies a highly sensitive population of sarcomas with significantly improved treatment outcome. Discussion: This retrospective study indicates that the DNA repair profile predicts improved outcomes in advanced sarcoma patients when treated with trabectedin. This clinical utility of this signature should be evaluated in prospective enriching studies in sarcoma and other malignancies for patients sensitive to trabectedin.",
keywords = "DNA repair, ET-743, Sarcoma, Trabectedin, Yondelis",
author = "P. Sch{\"o}ffski and M. Taron and J. Jimeno and F. Grosso and R. Sanfilipio and Casali, {P. G.} and {Le Cesne}, A. and Jones, {R. L.} and Blay, {J. Y.} and A. Poveda and Maki, {R. G.} and A. Nieto and Tercero, {J. C.} and R. Rosell",
year = "2011",
month = "5",
doi = "10.1016/j.ejca.2011.01.016",
language = "English",
volume = "47",
pages = "1006--1012",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin

T2 - A retrospective multicentric study

AU - Schöffski, P.

AU - Taron, M.

AU - Jimeno, J.

AU - Grosso, F.

AU - Sanfilipio, R.

AU - Casali, P. G.

AU - Le Cesne, A.

AU - Jones, R. L.

AU - Blay, J. Y.

AU - Poveda, A.

AU - Maki, R. G.

AU - Nieto, A.

AU - Tercero, J. C.

AU - Rosell, R.

PY - 2011/5

Y1 - 2011/5

N2 - Aim: Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair leads to resistance. On this basis, a retrospective study of mRNA expression of BRCA1 (breast cancer susceptibility 1 gene), XPG (Xeroderma pigmentosum group G gene) and ERCC1 (excision-repair cross complementing group 1 gene) in tumour samples from sarcoma patients treated with trabectedin was conducted, to correlate DNA repair profiles with patient outcome. Materials and methods: Quantification of expression in paraffin embedded tumour samples from 245 patients with advanced sarcomas was performed by qRT-PCR (quantitative real-time polymerase chain reaction). Median values were used as cut-off to define low/high mRNA expression. Results: Low BRCA1 mRNA expression in tumour samples correlated with statistically significant better response to trabectedin. In contrast to other DNA interacting agents, high expression of XPG was significantly correlated with increased response to the drug and high ERCC1 or XPD (Xeroderma pigmentosum group D gene) expression did not have a detrimental impact. A composite signature including low BRCA1 and high ERCC1 and/or XPG identifies a highly sensitive population of sarcomas with significantly improved treatment outcome. Discussion: This retrospective study indicates that the DNA repair profile predicts improved outcomes in advanced sarcoma patients when treated with trabectedin. This clinical utility of this signature should be evaluated in prospective enriching studies in sarcoma and other malignancies for patients sensitive to trabectedin.

AB - Aim: Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair leads to resistance. On this basis, a retrospective study of mRNA expression of BRCA1 (breast cancer susceptibility 1 gene), XPG (Xeroderma pigmentosum group G gene) and ERCC1 (excision-repair cross complementing group 1 gene) in tumour samples from sarcoma patients treated with trabectedin was conducted, to correlate DNA repair profiles with patient outcome. Materials and methods: Quantification of expression in paraffin embedded tumour samples from 245 patients with advanced sarcomas was performed by qRT-PCR (quantitative real-time polymerase chain reaction). Median values were used as cut-off to define low/high mRNA expression. Results: Low BRCA1 mRNA expression in tumour samples correlated with statistically significant better response to trabectedin. In contrast to other DNA interacting agents, high expression of XPG was significantly correlated with increased response to the drug and high ERCC1 or XPD (Xeroderma pigmentosum group D gene) expression did not have a detrimental impact. A composite signature including low BRCA1 and high ERCC1 and/or XPG identifies a highly sensitive population of sarcomas with significantly improved treatment outcome. Discussion: This retrospective study indicates that the DNA repair profile predicts improved outcomes in advanced sarcoma patients when treated with trabectedin. This clinical utility of this signature should be evaluated in prospective enriching studies in sarcoma and other malignancies for patients sensitive to trabectedin.

KW - DNA repair

KW - ET-743

KW - Sarcoma

KW - Trabectedin

KW - Yondelis

UR - http://www.scopus.com/inward/record.url?scp=79953706562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953706562&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.01.016

DO - 10.1016/j.ejca.2011.01.016

M3 - Article

VL - 47

SP - 1006

EP - 1012

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -